Investigating the effects of cold atmospheric plasma on peritoneal tumor tissue
Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue
This study is testing if a new treatment using cold plasma can help shrink tumor tissue in patients with peritoneal metastases before surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent, East-Flanders) |
| Trial ID | NCT06796634 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the effects of cold atmospheric plasma (CAP) on tumor tissue in patients with peritoneal metastases undergoing surgery. Tumor nodules will be treated with varying durations and intensities of CAP prior to surgical removal. The resected nodules will then be analyzed to assess tumor vitality and the potential impact of CAP treatment. This innovative approach seeks to provide insights into the efficacy of CAP in targeting tumor cells.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with peritoneal metastases from cancers such as ovarian cancer, colorectal cancer, or malignant peritoneal mesothelioma who are scheduled for surgery.
Not a fit: Patients with tumors not located in the peritoneum or those who are not undergoing surgical intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance surgical outcomes and improve survival rates for patients with peritoneal metastases.
How similar studies have performed: This approach is novel, as there are currently no existing studies examining the effects of cold atmospheric plasma on tumor tissue in patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients with peritoneal metastases undergoing surgery (CRS, debulking), irrespective of the origin. Potential cancer types include ovarian cancer, colorectal cancer, and malignant peritoneal mesothelioma * Written informed consent * Age ≥ 18 years.
Where this trial is running
Ghent, East-Flanders
- UZ Ghent — Ghent, East-Flanders, Belgium (Recruiting)
Study contacts
- Study coordinator: Wim Ceelen, professor
- Email: wim.ceelen@ugent.be
- Phone: +3293326251
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.